REGISTERED NUMBER: 12363962 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

BRISTOL SKIN CANCER LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTOR:

Dr. G. Mitsala

SECRETARY:

Dr. G. Mitsala

REGISTERED OFFICE:

128 Stoke Lane

Westbury-on-Trym

Bristol

Avon

BS9 3RJ

REGISTERED NUMBER:

12363962 (England and Wales)

ACCOUNTANTS:

LARKOS & PARTNERS

128 STOKE LANE

WESTBURY ON TRYM

BRISTOL

BS9 3RJ

FIXED ASSETS

Tangible assets

4

97,775

109,116

CURRENT ASSETS

Debtors

5

16,177

9,911

Cash at bank

43,460

20,406

59,637

30,317

CREDITORS

Amounts falling due within one year

6

51,027

28,587

NET CURRENT ASSETS

8,610

1,730

TOTAL ASSETS LESS CURRENT LIABILITIES

106,385

110,846

CREDITORS

Amounts falling due after more than one year

7

9,900

15,300

NET ASSETS

96,485

95,546

CAPITAL AND RESERVES

Called up share capital

8

1,000

1,000

Retained earnings

9

95,485

94,546

SHAREHOLDERS' FUNDS

96,485

95,546

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Director the director and authorised for issue on 20 August 2026 and were signed by:

Dr. G. Mitsala - Director

1.	STATUTORY INFORMATION

Bristol Skin Cancer Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery

-

15% on reducing balance

Fixtures and fittings

-

15% on reducing balance

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2024 - 1 ) .

4.	TANGIBLE FIXED ASSETS

Fixtures

Plant and

and

machinery

fittings

Totals

£

£

£

COST

At 1 January 2025

150,217

16,047

166,264

Additions

-

5,275

5,275

At 31 December 2025

150,217

21,322

171,539

DEPRECIATION

At 1 January 2025

50,474

6,674

57,148

Charge for year

14,961

1,655

16,616

At 31 December 2025

65,435

8,329

73,764

NET BOOK VALUE

At 31 December 2025

84,782

12,993

97,775

At 31 December 2024

99,743

9,373

109,116

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31/12/25

31/12/24

£

£

Trade debtors

9,179

5,831

Prepayments

6,998

4,080

16,177

9,911

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31/12/25

31/12/24

£

£

Trade creditors

-

1

Corporation Tax

5,157

3,323

Directors' current accounts

40,866

19,927

Accrued expenses

5,004

5,336

51,027

28,587

7.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

31/12/25

31/12/24

£

£

Bank Loan

9,900

15,300

8.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31/12/25

31/12/24

value:

£

£

500

Ordinary A

1

500

500

500

Ordinary B

1

500

500

1,000

1,000

9.

RESERVES

Retained

earnings

£

At 1 January 2025

94,546

Profit for the year

12,939

Dividends

(12,000

)

At 31 December 2025

95,485